|
Q4 2023
|
51 |
3,851,537 |
APLS, MRTX, PRTA, ARVN
|
13F-HR
|
2/14/2024 |
000093583624000163 |
|
Q3 2023
|
51 |
2,964,695 |
PRTA, APLS, MRTX, GLPG
|
13F-HR
|
11/14/2023 |
000093583623000696 |
|
Q2 2023
|
53 |
4,081,490 |
PRTA, APLS, SRPT, JNJ calls
|
13F-HR
|
8/14/2023 |
000093583623000570 |
|
Q1 2023
|
58 |
3,105,401 |
PRTA, SRPT, APLS, GLPG
|
13F-HR
|
5/15/2023 |
000093583623000412 |
|
Q4 2022
|
66 |
3,285,596 |
PRTA, SRPT, APLS, ANAB
|
13F-HR
|
2/14/2023 |
000093583623000229 |
|
Q3 2022
|
76 |
3,388,131 |
PRTA, APLS, SRPT, ANAB
|
13F-HR
|
11/14/2022 |
000156761922019766 |
|
Q2 2022
|
80 |
2,897,047 |
PRTA, APLS, SRPT, SGEN
|
13F-HR
|
8/15/2022 |
000156761922016025 |
|
Q1 2022
|
87 |
3,196,837 |
PRTA, APLS, GLPG, ANAB
|
13F-HR
|
5/16/2022 |
000156761922010677 |
|
Q4 2021
|
76 |
3,138,062 |
PRTA, ANAB, RCUS, XNCR
|
13F-HR
|
2/14/2022 |
000156761922003866 |
|
Q3 2021
|
71 |
2,874,475 |
PRTA, MORF, ANAB, RCUS
|
RESTATEMENT
|
11/22/2021 |
000156761921020941 |
|
Q2 2021
|
72 |
2,675,754 |
PRTA, MORF, ANAB, XNCR
|
13F-HR
|
8/16/2021 |
000156761921015658 |
|
Q1 2021
|
71 |
2,254,663 |
PRTA, XNCR, MORF, ANAB
|
13F-HR
|
5/17/2021 |
000156761921010348 |
|
Q4 2020
|
66 |
1,860,183 |
XNCR, RLAY, STTK, SPRY
|
13F-HR
|
2/16/2021 |
000156761921003800 |
|
Q3 2020
|
50 |
1,402,501 |
XNCR, KURA, RLAY, PRTA
|
13F-HR
|
11/16/2020 |
000156761920019716 |
|
Q2 2020
|
49 |
1,354,085 |
XNCR, PRTA, ORIC, MORF
|
13F-HR
|
8/14/2020 |
000156761920015276 |
|
Q1 2020
|
51 |
957,232 |
PRTA, XNCR, ARVN, DRNA
|
13F-HR
|
5/15/2020 |
000156761920010491 |
|
Q4 2019
|
44 |
1,109,471 |
PRTA, XNCR, DRNA, FGEN
|
RESTATEMENT
|
2/18/2020 |
000156761920004215 |
|
Q3 2019
|
38 |
791,886 |
XNCR, PRTA, ONCE, KURA
|
13F-HR
|
11/14/2019 |
000156761919021573 |
|
Q2 2019
|
39 |
989,642 |
KURA, XNCR, ARGX, CRSP
|
13F-HR
|
8/14/2019 |
000156761919017041 |
|
Q1 2019
|
41 |
1,084,777 |
ARGX, KURA, MRTX, CRSP
|
13F-HR
|
5/15/2019 |
000156761919011227 |
|
Q4 2018
|
53 |
999,389 |
ARGX, KURA, FGEN, IRWD
|
13F-HR
|
2/14/2019 |
000156761919004400 |
|
Q3 2018
|
50 |
1,110,045 |
FGEN, ASMB, IRWD, ASND
|
13F-HR
|
11/14/2018 |
000156761918006356 |
|
Q2 2018
|
33 |
1,050,372 |
FGEN, IRWD, ASMB, ASND
|
13F-HR
|
8/14/2018 |
000156761918000858 |
|
Q1 2018
|
31 |
997,012 |
ASMB, ASND, FGEN, IRWD
|
13F-HR
|
5/15/2018 |
000114036118023901 |
|
Q4 2017
|
30 |
888,086 |
ASMB, FGEN, CELGENE CORPORATION calls, IRWD
|
13F-HR
|
2/14/2018 |
000114036118007942 |
|
Q3 2017
|
39 |
750,316 |
ASMB, FGEN, IRWD, ASND
|
13F-HR
|
11/14/2017 |
000114036117042799 |
|
Q2 2017
|
36 |
563,229 |
ALEXION PHARMACEUTICALS, INC calls, IRWD, ASMB, FGEN
|
13F-HR
|
8/14/2017 |
000114036117032004 |
|
Q1 2017
|
33 |
395,567 |
ASMB, IRWD, GLPG, GILEAD SCIENCES INC calls
|
RESTATEMENT
|
5/19/2017 |
000114036117021481 |
|
Q4 2016
|
30 |
299,427 |
IRWD, GLPG, ASMB, ALXN
|
RESTATEMENT
|
2/15/2017 |
000114036117007745 |
|
Q4 2016
|
1 |
14,684 |
FGEN
|
NEW HOLDINGS
|
2/15/2017 |
000114036117007752 |
|
Q3 2016
|
31 |
325,892 |
IRWD, GLPG, BRISTOL MYERS SQUIBB CO calls, ASMB
|
13F-HR
|
11/14/2016 |
000114036116086430 |
|
Q2 2016
|
32 |
253,622 |
IRWD, GLPG, TVTX, CYTK
|
13F-HR
|
8/15/2016 |
000114036116076455 |
|
Q1 2016
|
37 |
286,194 |
IRWD, FPRX, EPZM, FGEN
|
13F-HR
|
5/16/2016 |
000114036116065705 |
|
Q4 2015
|
31 |
318,400 |
FGEN, FPRX, JAZZ PHARMACEUTICALS calls, TVTX
|
13F-HR
|
2/16/2016 |
000114036116052684 |
|
Q3 2015
|
25 |
219,698 |
FGEN, ATRA, ARRAY BIOPHARMA INC, TVTX
|
13F-HR
|
11/16/2015 |
000114036115041435 |
|
Q2 2015
|
25 |
299,936 |
ATRA, EPZM, ASMB, FGEN
|
13F-HR
|
8/14/2015 |
000114036115031882 |
|
Q1 2015
|
23 |
300,071 |
ATRA, EPZM, RCPT, ARRAY BIOPHARMA SR CONV NT 3.000% Due 06/01/2020
|
RESTATEMENT
|
5/18/2015 |
000114036115020512 |
|
Q4 2014
|
22 |
197,602 |
KITE, CLVSQ, RCPT, ARRAY BIOPHARMA INC
|
13F-HR
|
2/17/2015 |
000092189515000435 |